Straight Path Wealth Management Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Straight Path Wealth Management bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,706 shares of the biopharmaceutical company’s stock, valued at approximately $435,000.

Several other large investors have also added to or reduced their stakes in GILD. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC grew its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Citigroup initiated coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Finally, Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $104.24.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 293,356 shares of company stock valued at $29,166,240 over the last ninety days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $115.44 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a fifty day simple moving average of $98.71 and a two-hundred day simple moving average of $90.91. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $117.39. The company has a market capitalization of $143.87 billion, a P/E ratio of 312.00, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.